1.
Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomib.
by Shiga, Kensuke
December 2010
Journal of neurology, Vol.257(12), pp.2091-2093
2010
2.
Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib
by Poon, L-M
Bone Marrow Transplantation, Jun 2012, pp.870-1
3.
A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment
by Mauermann, Michelle L.
Muscle & Nerve, Dec 2012, Vol.46(6), pp.970-7
4.
Additive effect of tetramethylpyrazine and deferoxamine in the treatment of spinal cord injury caused by aortic cross-clamping in rats
by Liang, Y
Spinal Cord, Feb 2011, pp.302-6
5.
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
by Mazumder, Amitabha
Clinical lymphoma, myeloma & leukemia, April 2010, Vol.10(2), pp.149-151
6.
Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review
by Besada, Emilio
International Journal of Hematology, Jun 2013, pp.800-3
7.
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
by Zago, Manola
Annals of hematology, December 2014, Vol.93(12), pp.1993-1999
8.
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
by Li, Tianhong
Lung cancer (Amsterdam, Netherlands), April 2010, Vol.68(1), pp.89-93
9.
Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B.
by Ceresa, Cecilia
Anticancer research, January 2014, Vol.34(1), pp.517-523
10.
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
by Hobeika, Liliane
BMC nephrology, September 30, 2014, Vol.15, p.156
11.
Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients.
by Paolisso, G
The American journal of cardiology, October 1, 1997, Vol.80(7), pp.932-937
12.
Bortezomib-associated tumor lysis syndrome in multiple myeloma.
by Furtado, Michelle
December 2008
Leukemia & lymphoma, Vol.49(12), pp.2380-2382
2008
13.
Response to bortezomib in refractory type I cryoglobulinemia.
by Talamo, Giampaolo
November 2008
American journal of hematology, Vol.83(11), pp.883-884
2008
14.
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration
by Terpos, Evangelos
Journal of Cancer Research & Clinical Oncology, Oct 2004, pp.623-5
15.
Bortezomib-related colon mucositis in a multiple myeloma patient
by Siniscalchi, Agostina
Supportive Care in Cancer, Apr 2009, Vol.17(4), pp.325-7
16.
Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report
by Yates, Sean
Transfusion, Aug 2014, pp.2064-7
17.
Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
by Kenealy, Melita K
Pharmacotherapy, August 2006, Vol.26(8), pp.1205-6; discussion 1206
18.
Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
by Jaskiewicz, Adam D
Pharmacotherapy, December 2005, Vol.25(12), pp.1820-1825
19.
Inhibitory effects of ligustrazine, a modulator of thromboxane-prostacycline-nitric oxide balance, on renal injury in rats with passive Heyman nephritis.
by Wang, Yingwei
Nephron. Physiology, 2004, Vol.98(3), pp.p80-p88
20.
Antithrombotic Effects of Tetramethylpyrazine in In Vivo Experiments
by Sheu, Joen
International Journal of Hematology, Apr 2001, pp.393-8
